The present invention relates to a method for purifying N-substituted maleimide. More particularly, the present invention adopts an evaporation apparatus, which can previously remove impurities having higher boiling points than the N-substituted maleimide after removing an organic solvent from an N-substituted maleimide resulting solution, thereby achieving effects of minimizing the pressure loss and polymerization loss, and obtaining high-purity N-substituted maleimide.

The present invention relates to a method for purifying N-substituted maleimide. More particularly, the present invention adopts an evaporation apparatus, which can previously remove impurities having higher boiling points than the N-substituted maleimide after removing an organic solvent from an N-substituted maleimide resulting solution, thereby achieving effects of minimizing the pressure loss and polymerization loss, and obtaining high-purity N-substituted maleimide.

The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.

The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.

The present invention relates to a method for purifying N-substituted maleimide. More particularly, the present invention adopts an evaporation apparatus, which can previously remove impurities having higher boiling points than the N-substituted maleimide after removing an organic solvent from an N-substituted maleimide resulting solution, thereby achieving effects of minimizing the pressure loss and polymerization loss, and obtaining high-purity N-substituted maleimide.

The present invention relates to a method for purifying N-substituted maleimide. More particularly, the present invention adopts an evaporation apparatus, which can previously remove impurities having higher boiling points than the N-substituted maleimide after removing an organic solvent from an N-substituted maleimide resulting solution, thereby achieving effects of minimizing the pressure loss and polymerization loss, and obtaining high-purity N-substituted maleimide.

Disclosed herein, are 5-Aminolevulinate synthase inhibitors and methods for their use in the treatment of porphyria. In at least one specific embodiment, the 5-Aminolevulinate synthase inhibitors can include compounds or salts thereof of Formulas (I-V).

##STR00001##

Disclosed herein, are 5-Aminolevulinate synthase inhibitors and methods for their use in the treatment of porphyria. In at least one specific embodiment, the 5-Aminolevulinate synthase inhibitors can include compounds or salts thereof of Formulas (I-V).

##STR00001##

Provided is a maleimide resin with superior solution stability. Also provided is a cured product with a superior dielectric characteristic that is obtained by curing a curable resin composition in which said maleimide resin is used. The maleimide resin expressed in formula (1). (In formula (1), each of the plurality of Rs independently represents a C1-5 alkyl group, n is the number of repetitions, and the average value thereof is 1<n<5.)

In an embodiment of the invention, a composition for treating a cell population comprises a medicant. The medicant moiety can be an illudofulvene analog. In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The affinity moiety can be an antibody, an antibody fragment, a receptor protein, a peptidic growth factor, an anti-angiogenic protein, a specific binding peptide, protease cleavable peptide, a glycopeptide, a peptide, a peptidic toxin, a protein toxin and an oligonucleotide. The affinity moiety can be covalently bound to the medicant via a linker.